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Key questions
What is already known about this subject?
 ► The benefits of secondary prevention medicines 
(SPM) post-myocardial infarction (MI) are substantial 
and well established. However, there is plenty of evi-
dence to show that many opportunities are missed 
by not prescribing these medicines at optimal doses 
and/or by lack of adherence to these medicines. It is 
estimated that up to 50% of patients do not take at 
least one of their SPM as prescribed. Interventions 
to improve adherence cannot be one size fit all, they 
need to be tailored to patient’s needs.
What does this study add?
 ► The study introduces a new model of working which 
involves the support of a cardiology consultant phar-
macist and a review of patients’ medicines needs 
post-MI. It offers the patients the opportunity to 
identify any actual and potential barriers to SPM 
adherence to be addressed in the first outpatient 
cardiology clinic. The new model improved levels 
of optimisation of SPM, addressed concerns about 
SPM, reduced self-reported non-adherence, acute 
coronary syndrome readmissions (compared to be-
fore service introduced) and improved persistence 
with guidelines recommended SPM at 12 months 
postdischarge.
How might this impact on clinical practice?
 ► The new model shows the need to re-examine how 
outpatient follow up is arranged post-MI in terms of 
patient’s needs, healthcare professionals involved 
and adopting a new approach based on the prin-
ciples of medicines optimisation and adherence to 
deliver a more patient-centred medicines review. 
This is likely to improve outcomes and reduce many 
missed opportunities post-MI.
AbstrAct
Background Inadequate medicines optimisation and 
adherence are significant problems among patients taking 
secondary prevention medications following myocardial 
infarction (MI). A novel joint consultant cardiology 
pharmacist and cardiologist medicines optimisation clinic 
was initiated for patients recently discharged following MI.
Methods Patients completed a locally developed tool, 
the ‘My Experience of Taking Medicines’ questionnaire, 
designed to allow sharing of barriers to adherence 
with medications. They then attended a clinic with the 
consultant pharmacist or cardiologist (or both). Secondary 
prevention medicines needs and barriers to adherence 
were identified and discussed, and an action plan 
developed. The data provided are from a retrospective 
review of 270 post-MI patients attending the service 
between October 2015 and December 2016.
Results Mean age was 67.3 years and 67.8% were 
male. The mean time from discharge to first outpatient 
clinic attendance was reduced by 56.1% (49.4 days vs 
88 days before the service began). More than 95% of 
patient without planned non-pharmacological intervention 
postdischarge did not need a cardiologist’s input. Levels 
of medicines optimisation were improved substantially 
after attendance: patients receiving a recommended 
angiotensin-converting enzyme inhibitor/angiotensin 
receptor blocker dose increased from 16.3% to 73.9% 
(p<0.001); patients receiving a recommended beta-
blocker dose increased from 6.2% to 46.1% (p<0.001). 
Patient concerns about their medications were significantly 
decreased (all p<0.001). Rates of non-adherence fell by 
42.6%–70.8% at 3–6 months post-clinic. Readmission 
rates also declined after the service opened.
Conclusions A medicines optimisation and patient 
adherence strategy based on a joint consultant cardiology 
pharmacist and cardiologist clinic can improve both 
adherence and outcomes post-MI.
IntRoduCtIon
In patients who have experienced a myocar-
dial infarction (MI), it is essential to initiate 
a long-term programme of secondary 
prevention through risk factor modifica-
tion.1–3 Optimisation of drug therapies is a 
key element of this, ensuring that patients 
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are receiving all of the required classes of treatment at an 
appropriate dose.
However, in a prospective, observational study 
conducted at a centre in the UK, more than 25% of 
patients with pre-existing coronary heart disease who 
were readmitted with an acute coronary syndrome 
were receiving a suboptimal secondary prevention drug 
regimen.4 Many of these patients were not achieving 
cholesterol and blood pressure targets, which could have 
been a major contributor to their re-presentation to 
hospital.
Furthermore, even among patients who are prescribed 
an optimal secondary prevention regimen, non-adher-
ence can be a significant problem. Up to half of all medi-
cines prescribed for long-term conditions may not be 
taken as recommended, with significant potential impli-
cations for the patient, healthcare system and society as 
a whole.5 A meta-analysis of data from almost 400 000 
patients from 20 studies assessing adherence to drugs 
that prevent cardiovascular disease estimated that adher-
ence was around 57% after a median of 24 months.6 The 
impact on outcomes can be substantial. For example, 
among patients with elevated cholesterol prescribed a 
statin, non-adherence was associated with a 26% increase 
in cardiovascular-related hospitalisations compared with 
adherent patients.7 In a recent meta-analysis, the relative 
risks of all-cause mortality in patients with good versus 
poor (<80%), adherence were 0.55 and 0.71 in those 
taking statins and antihypertensive agents, respectively.8 
More specifically in secondary prevention, adherence 
with medications post-MI has been shown to decrease 
the likelihood of readmission for a cardiovascular-related 
issue.8
Local data from 500 patients with coronary artery 
disease in the West Yorkshire area of the UK found that 
44% were not adherent to at least one secondary preven-
tion medicine.9 To try to address this issue, a novel joint 
consultant cardiology pharmacist and cardiologist medi-
cines optimisation clinic was initiated for patients who 
have recently been discharged following MI. The aims 
were to ensure that patients receive a comprehensive 
review of their secondary prevention medicine needs; to 
allow patients to share their medicines-taking experience 
and receive the necessary support to maximise benefit 
and minimise the risk of adverse drug reactions and, ulti-
mately, to improve patient outcomes.
MetHods
service design
The post-MI medicines optimisation multidisciplinary 
team (MDT) clinic was initiated in October 2015, as a 
collaboration between the Cardiology and Pharmacy 
Departments of Leeds Teaching Hospitals National Health 
Service Trust. Initially, it operated as a pilot programme, 
but the service development project was later continued 
on a larger scale as part of a joint working agreement 
between Leeds Teaching Hospitals and AstraZeneca.
Consecutive patients from the city of Leeds, UK, 
who were admitted to Cardiology with MI were triaged 
to attend a post-discharge follow-up clinic in the new 
service. In advance of that visit, patients were sent a 
locally developed tool known as the ‘My Experience of 
Taking Medicines’ (MYMEDS) questionnaire. This tool 
was specifically designed to enable patients to share any 
actual or potential barriers that they may have with adher-
ence to secondary prevention medicines.
Patients then attended the post-MI medicines optimis-
ation MDT clinic. Patients who did not need any further 
non-pharmacological interventions saw the consultant 
cardiology pharmacist with the option of a review by a 
cardiologist if needed. Patients who did need further 
interventions (eg, staged percutaneous coronary inter-
vention) saw a cardiologist, with the option of referral 
to the consultant pharmacist. Support was provided by a 
cardiology research nurse to collect data.
Most patients attended the ‘Standard Medicines Opti-
misation Clinic’, typically lasting 20–25 min; however, 
post-MI patients with complex medicines-related issues 
(eg, documented or high risk for poor adherence or 
intolerance to any secondary prevention medicines) 
attended an ‘Advanced Medicines Optimisation Clinic’, 
which included a longer consultation (around 45 min), 
allowing time to conduct a thorough review.
Both types of consultations took a patient-centred 
approach, striving first to meet the needs of the indi-
vidual concerned. Secondary prevention medicines and 
barriers to adherence were identified and discussed 
based on MYMEDS.
Following on from the consultation, patients were 
provided with a summary of the discussions and a full 
management plan, including the main action points. To 
ensure continuity of care, this was also shared with their 
general practitioner (GP) and with the cardiac rehabili-
tation team.
The present analysis is a retrospective review of data 
from 270 post-MI patients attending the service between 
October 2015 and December 2016. It was conducted in 
accordance with the World Medical Association Decla-
ration of Helsinki. As this was a service development 
project, in line with local policy, no Ethics Committee 
approval was needed. However, the project had a steering 
committee that monitored the project and tracked its 
progress on a quarterly basis. The committee included 
the clinical directors of cardiology and pharmacy, cardi-
ologists, pharmacists, a cardiology nurse, a GP and an 
AstraZeneca representative and had input from a patient 
representative.
Assessments
Patients completed the My Experience of Taking Medi-
cine (MYMEDS) questionnaire before attending the 
clinic and brought it with them for discussion during the 
consultation.
Within the MYMEDS questionnaire, patient listed the 
medicines that they were taking and these were assessed 
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against national and international guideline recommen-
dations. Patients were asked about their understanding of 
why these medicines were prescribed, any concerns they 
had about them and any practical barriers to taking them 
and were also asked to report whether they took each 
of their medicines as recommended by the prescriber. 
The answers were used to estimate levels of self-reported 
non-adherence. Optimisation of the doses of secondary 
prevention medicines (ACE inhibitors, angiotensin 
receptor blockers (ARBs), beta blockers, statins, anti-
platelet agents and eplerenone where indicated) was 
considered during the clinic. Further review was made of 
other antianginal drugs and the need for gastroprotec-
tive drugs, if required.
After attendance, patients were also asked to rate 
their experience of the clinic using an anonymous 
feedback questionnaire offered at the end of the clinic, 
which they could send back at their convenience using 
a prepaid envelope. This questionnaire also assessed 
changes in their overall levels of concern about their 
medicines.
Patient self-reported adherence with individual 
secondary prevention medicines was re-evaluated 3–6 
months post-clinic by asking patients to redo the relevant 
section of the MYMEDS questionnaire.
Prescription persistence with guidelines recommended 
secondary prevention medications was also assessed, at 
11–12 months postdischarge, based on a sample of 50 
patients managed by the consultant cardiology pharma-
cist within the medicines optimisation clinic. This was 
done remotely by reviewing their prescriptions and elec-
tronic records. Patients were given a persistence score 
using a locally developed tool (the ‘Secondary Preven-
tion Prescription Persistence Score’ tool), based on the 
expected post-MI secondary prevention medications 
prescribed, the doses of beta blockers and ACE inhibitors 
(or ARBs) and eplerenone if ejection fraction ≤40%. A 
score of 100% was given for patients prescribed all of the 
recommended medicines at the recommended doses. 
Patients scoring <70% were deemed to be non-persistent. 
Rates of non-persistence were compared against a sepa-
rate cohort of 50 post-MI patients (not needing further 
non-pharmacological interventions) going through the 
old service (ie, seen by a cardiologist outside the remit of 
the medicines optimisation clinic).
Finally, changes at system level following initiation of 
the medicines optimisation clinic were also evaluated. 
These included changes in mean patient waiting time 
from discharge to first outpatient cardiology review 
and changes in acute coronary syndrome (ACS)-related 
hospital readmission rates at 30, 60 and 90 days after 
discharge after initiation of the service (1 October 2015 
to 24 July 2016 (after this date, there were changes to 
the outpatient clinics that complicated comparison)) 
compared with a year before (1 October 2014 to 30 
September 2015) as a baseline.
statistical analyses
Descriptive statistics are provided. The baseline charac-
teristics of patients who completed the questionnaire 
versus those who did not were compared using the inde-
pendent samples t-test and χ2 test. The McNemar test was 
used to compare the proportion of patients receiving 
recommended doses of ACE inhibitors/ARBs, beta 
blockers, eplerenone and gastroprotective drugs, where 
indicated, before and after attending the clinic. Levels of 
patient concerns about their medicines before and after 
attending the clinic were assessed using the χ2 test. The 
χ2 test was also used to assess adherence with individual 
secondary prevention medicines before and after the 
clinic. For the prescription persistence data, two inde-
pendent samples t-test was used to compare means and 
χ2 test to compare number of patients who attended the 
new and old service and had a score of <70% using SPSS 
V.20. All reported p values were two tailed.
Results
demographics
A total of 270 patients with MI who had completed their 
clinic experience before the cut-off date were included 
in the present analysis. Baseline patient characteristics 
are provided in table 1. In total, 183 (67.8%) were male, 
and the mean age was 67.3 years (range 33–95 years). 
Ninety-nine (36.7%) had an ST-elevation MI (STEMI) 
and 171 (63.3%) were patients with non-ST-elevation 
MI (NSTEMI). The majority had no history of prior MI 
(n=207; 76.7%).
Most patients (n=238; 88.1%) attended the standard 
rather than the advanced clinic. The mean time since 
discharge on attending the clinic was 49.4 days (range 
9–195 days). Some patients were referred to the clinic 
rather than coming straight from discharge as per the 
normal pathway; if referred patients were excluded, the 
mean time to attending the clinic was 45.6 days (range 
9–93 days).
Around a quarter of patients did not complete the 
questionnaire, either because they said that they did not 
receive it in the post or because they did not complete 
it and preferred instead to discuss the issues in person 
during the clinic. There were no significant differences 
in baseline characteristics between those who completed 
the questionnaire and those who did not, other than age 
(mean age 66.2±14.5 years among non-respondents vs 
70.5±10.9 years among respondents; p=0.022).
Medicines optimisation
Levels of medicines optimisation were improved substan-
tially among patients attending the clinic. The propor-
tion of patients receiving a recommended dose of an 
ACE inhibitor or ARB (where tolerated and not already 
on maximum dose at discharge) increased from 16.3% 
(n=33/203) to 73.9% (n=150/203) (all uptitrated) 
(p<0.001). The remaining 26.1% of patients (n=53/203) 
who were on an ACE inhibitor or ARB could not be 
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Table 2 Key changes in patient concerns before and up 
to a month after attending the medicines optimisation clinic 
(MYMEDS)
Issue identified Before clinic After clinic P value
Patient understands the 
reason for their cardiac 
medicines
143/196 (73.0) 192/194 (99.0) <0.001
Patient concern that cardiac 
medicines will do more 
harm than good
62/187 (33.2) 6/190 (3.2) <0.001
Patient sometimes forgets to 
take medicines
39/193 (20.2) 6/172 (3.5) <0.001
Data are n(%).
MYMEDS, My Experience of Taking Medicines questionnaire.
Table 1 Baseline patient characteristics
Variable
Baseline value 
(N=270)
Sex, n (%) 
  Male 183 (67.8)
  Female 86 (31.9)
  Not recorded 1 (0.4)
  Age (years), mean (range) 67.3 (33–95)
Type of MI, n (%) 
  STEMI 99 (36.7)
  NSTEMI 171 (63.3)
History of prior MI, n (%) 
  Yes 35 (13.0)
  No 207 (76.7)
  Not recorded 28 (10.4)
Comorbidities, n (%) 
  Diabetes (any type) 57 (21.1)
  Hypercholesterolaemia 40 (14.8)
  Hypertension 99 (36.7)
  Left ventricular systolic dysfunction 9 (3.3)
  Chronic obstructive pulmonary disease 24 (8.9)
Time since discharge (days), mean (range) 49.4 (9–195)
Type of intervention, n (%) 
  Medical management 76 (28.1)
  Percutaneous coronary intervention 194 (71.9)
Type of clinic at first visit, n (%) 
  Standard 238 (88.1)
  Advanced 32 (11.9)
MI, myocardial infarction; NSTEMI, non-ST-elevation myocardial 
infarction; STEMI, ST-elevation myocardial infarction.
uptitrated (eg, due to hypotension or poor renal func-
tion) or needed their dose to be downtitrated (eg, due to 
hypotension or dizziness).
The proportion of patients receiving a recommended 
beta blocker dose (where tolerated and not already 
on maximum dose at discharge) increased from 6.2% 
(n=15/241) to 46.1% (n=111/241) (all uptitrated) 
(p<0.001). The remaining 53.9% (n=130/241) either 
could not tolerate any further uptitration or uptitration 
could not be made in clinic (eg, due to an ACE inhibitor 
being uptitrated at the same time).
Antianginal drugs were optimised in 17.0% of patients 
(n=46/270). Similarly, 20.8% of patients (n=54/259) 
had their statin dose optimised (initiated a high-inten-
sity statin, challenged non-tolerance or uptitrated in line 
with guidelines) and 14.1% (n=37/262) had their second 
antiplatelet dose optimised (switched due to side effects, 
or changed in line with triple therapy guidelines). Epler-
enone and gastric protection were initiated in 82.4% 
(n=14/17) and 25.0% (n=15/60) of patients, respec-
tively, in whom they were indicated and who were not 
already receiving them. Hence, the number of patients 
who were suitable and initiated on eplerenone after 
attending the clinic was 93.0% (n=40/43) compared 
with 60.5% (n=26/43) before the clinic (p<0.001). Simi-
larly, the number of patients who were prescribed gastric 
protection, where indicated, increased from 65.3% 
(n=113/173) pre-clinic to 74.0% (n=128/173) after the 
clinic (p<0.001).
Patient concerns about secondary prevention
Among patients who completed the MYMEDS ques-
tionnaire before attending the medicines optimisa-
tion clinic (N=204), 73.0% (n=143/196) of those who 
answered this section said that they understood the 
reasons for their cardiac medicines (table 2). However, 
33.2% (n=62/187) of those who answered this section 
expressed concern that their cardiac medicines would 
do more harm than good. After attending the clinic, 
feedback questionnaire responses (returned within a 
month post-clinic) showed that almost all patients felt 
that they now understood the reasons for their cardiac 
medicines (99.0%; n=192/194) and few continued 
to believe that the medicines would do more harm 
than good (3.2%; n=6/190) (p<0.001 compared with 
before the clinic). The proportion of patients who said 
that they sometimes forget to take their medicine also 
decreased from 20.2% (n=39/193) before the clinic to 
3.5% (n=6/172) afterwards (p<0.001).
Patient experience of the service
After attendance, patients were asked to rate their expe-
rience of the medicines optimisation clinic. Among 190 
individuals who responded, the service was given a mean 
of score of 9.5 on a scale of 0 (very poor) to 10 (excel-
lent). Furthermore, 77.6% (n=152/196) strongly agreed 
and 22.4% (n=44/196) agreed that, overall, the clinic was 
valuable and they would recommend it for patients with 
heart disease (table 3). No patients disagreed.
When questioned about individual aspects of their 
participation in the clinic, such as having their questions 
answered and being involved in decision-making, 100% 
of patients either agreed or strongly agreed that it had 
been a positive experience (table 3).
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Table 3 Patient’s experience of the medicines optimisation clinic
Strongly 
disagree Disagree Agree
Strongly 
agree
I felt that I was listened to (N=200) 0 0 47 (23.5) 153 (76.5)
All questions and concerns about my medicines were answered (N=202) 0 0 55 (27.2) 147 (72.8)
I felt reassured by the consultant cardiology pharmacist (N=201) 0 0 43 (21.4) 158 (78.6)
I felt involved in the discussion and any decisions made were in agreement with me (N=201) 0 0 47 (23.4) 154 (76.6)
This was a valuable clinic that I would recommend for patients with heart disease (N=196) 0 0 44 (22.4) 152 (77.6)
Data are n (%).
Table 4 Self-reported non-adherence to individual secondary prevention medicines before and after the medicines 
optimisation clinic
Secondary prevention 
medicine
Non-adherence rate 
prior to clinic
Non-adherence rate 3–6 
months post-clinic
Relative reduction in 
non-adherence P value
ACE inhibitor /ARB 27/178 (15.2%) 10/130 (7.7%) 49.3% 0.046
Beta blocker 23/169 (13.6%) 5/119 (4.2%) 69.1% 0.008
Statin 39/181 (21.5%) 8/127 (6.3%) 70.8% <0.001
Clopidogrel/prasugrel/ticagrelor 32/173 (18.5%) 7/126 (5.6%) 69.7% 0.001
Aspirin 24/176 (13.6%) 10/128 (7.8%) 42.6% 0.112
ARB, angiotensin receptor blocker.ACE, Angiotensin-Converting Enzyme.
non-adherence and prescription non-persistence
When attending the medicines optimisation clinic, 
rates of patient-reported non-adherence with individual 
secondary prevention medicines ranged between 13.6% 
and 21.5% for different drug classes (table 4). When 
assessed again at 3–6 months after the clinic, rates of 
non-adherence had fallen to 4.2%–7.8%. This equates to 
relative reductions in rates of non-adherence of 42.6%–
70.8% for the various classes of drugs. All of these reduc-
tions were statistically significant, apart from that relating 
to aspirin.
Prescription persistence with secondary prevention 
medications was assessed at 11–12 months post-MI 
discharge in a sample of 50 consecutive patients managed 
by the consultant cardiology pharmacist under the 
auspices of the medicines optimisation clinic. Results 
were compared against persistence among 50 consecu-
tive patients treated under cardiologist care outside of 
the medicines optimisation clinic. Mean prescription 
persistence scores (SD, range) were 83.1% (9, 64–100) 
and 76.5% (12, 43–100), respectively (p=0.002). Rates 
of non-persistence (ie, a persistence score <70%) were 
10.0% (n=5) and 34.0% (n=17), respectively, in patients 
attending or not attending the medicines optimisation 
clinic (p=0.004).
Waiting times
The medicines optimisation clinic led to a 44% reduction 
in mean waiting times from discharge to first outpatient 
cardiology review, from 88 days before the service to 49 
days once the service began. Furthermore, the majority 
of patients were seen only by the consultant cardiology 
pharmacist, with fewer than 5% requiring input from a 
cardiologist.
Readmission rates
The service was associated with a decrease in readmission 
rates. Compared with the previous year as a baseline, the 
proportion of patients readmitted to hospital with ACS 
within 30, 60 and 90 days of discharge was reduced by 
42.9% (from 7% to 4%), 50.0% (from 10% to 5%) and 
54.6% (from 11% to 5%), respectively, after the service 
began operating.
dIsCussIon
The present study showed the positive impact of a novel 
post-MI clinic, which provided access to a consultant cardi-
ology pharmacist or a cardiologist or both, on a range of 
measures, including optimisation of secondary preven-
tion medicines and patient adherence. It demonstrates 
that collaboration and multidisciplinary working are 
central to the delivery of effective medicines optimisation. 
However, although patients had access to both a consultant 
cardiology pharmacist and a cardiologist, as needed, 
the majority of patients (>95%) were seen only by the 
consultant cardiology pharmacist. Hence, this new service 
freed-up cardiology outpatient clinics and created more 
outpatient capacity. Importantly, patients were happy with 
the arrangement despite not being seen by the cardiolo-
gist; on the contrary, most were pleased with the pharmacist 
consultation and with the service in general as it adopted a 
patient-centred approach.
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The mean time from discharge to clinic attendance was 
around 7 weeks (49.4 days), which was substantially lower 
than the mean waiting time to first outpatient cardiology 
review before the service began (88 days). One of the key 
early learnings of the project was the need to improve 
the outpatient booking system, and once that had been 
improved, patients were seen even more rapidly.
The model aligns with UK guidance from the National 
Institute for Health and Care Excellence (NICE), which 
recommends that structured medicines reviews should be 
considered for all patients with long-term conditions and/
or taking multiple medicines.10 This guidance also notes 
that organisations should decide locally on the most appro-
priate healthcare professional to lead these reviews, within 
the context of an MDT, and that a pharmacist may be an 
appropriate choice.10 The recent Carter review of produc-
tivity and performance in English NHS acute hospitals 
proposed that local trusts should deploy more clinical phar-
macists, including pharmacist prescribers, to drive value in 
medicines spending, including optimisation activities.11
From an international perspective, a pharmacist-led 
model of medicines optimisation may not be applicable 
in all countries, particularly those where non-physician 
prescribing is not possible or where the role of the clinical 
pharmacist is less developed. However, structured reviews 
led by a physician rather than a pharmacist can be under-
taken post-MI in most developed healthcare systems, and 
this work demonstrates their potential value.
The model adopted in this study aligned with the princi-
ples of medicines optimisation and adherence defined by 
NICE.5 10 In particular, the MYMEDS questionnaire enabled 
patients to think about actual or potential issues that might 
affect their ability to take their medicines and to derive 
maximum benefit from them. Furthermore, the consulta-
tion embraced a patient-centred approach and focused on 
the concerns that they highlighted in the MYMEDS ques-
tionnaire. Patients were encouraged to come primed with 
all of their questions and felt that the clinic was particularly 
fulfilling because it addressed their needs. They also felt 
more involved. Overall, this approach brought to reality the 
concept of ‘shared decision-making’, which is frequently 
recommended3 5 10 but often difficult to deliver.
As a result, not only were secondary prevention medi-
cines optimised but also substantial improvements in 
adherence were also achieved. This may have resulted from 
increased patient understanding of their medicines and the 
creation of specific action plans for overcoming barriers to 
adherence.
The association between improved adherence and 
improved long-term outcomes is well established.7 8 12 
However, a recent Cochrane review of 182 trials of inter-
ventions designed to improve adherence to prescribed 
medications highlighted a lack of techniques with substan-
tial impact on both adherence and outcomes.13 It is there-
fore encouraging that the present study was associated not 
only with an improvement in adherence but also improved 
outcomes, in the form of reduced hospital readmission 
rates at 30, 60 and 90 days postdischarge. Although the 
mean time between discharge and attending the medicines 
optimisation clinic was 49 days across the data set, 22% of 
patients were seen within 30 days.
We must acknowledge some important limitations of the 
present study, in particular its retrospective design and the 
lack of a comparator arm for most outcome measures. A 
prospective, randomised controlled trial would certainly 
be valuable. In addition, self-reported adherence has its 
limitations, particularly with respect to overestimation. 
Adherence behaviour changes over time, and hence it 
would be useful to remeasure over longer-term time points. 
Another limitation that should be acknowledged is that 
the findings only apply to patients who did not need any 
further non-pharmacological coronary interventions post 
discharge. Not all patients completed the questionnaire 
and those who did not tended to be younger. Finally, there 
was a statistical analysis limitation resulting from the design 
of the study. While more powerful statistics could have been 
performed on paired data, not all of data could be paired 
because patient anonymity was offered in some question-
naires to reduce the risk of social desirability. Despite this, 
suitable statistical analyses were applied.
However, overall, the current study demonstrates that 
a medicines optimisation and patient adherence strategy 
based on a primarily pharmacist-led clinic supported by a 
cardiologist can improve both adherence and outcomes 
post-MI.
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